Gastroenterologists increasingly see patients with symptoms after bariatric surgery. A number of gastrointestinal or extra-gastrointestinal symptoms should raise the suspicion of malabsorption or dumping syndrome. Little is known about long-term consequences of disordered intestinal anatomy and physiology resulting from bariatric surgical procedures. The latency phase of clinical problems is unknown, but may potentially be long, and postoperative courses over many decades have to be considered regarding the consequences of surgical alterations of gastrointestinal structure and function. Long-term nutritional requirements in patients with bariatric procedures are incompletely understood. This review focuses on the pathophysiology of long-limb Roux-en-Y gastric bypass (RYGB) because it has become the most common bariatric procedure in many parts of the world. Although several potential mechanisms for nutritional deficiencies after RYGB like deficiency of dietary intake, lack of gastric secretions, exclusion of proximal duodenum and jejunum, or asynergia between food bolus and biliopancreatic secretions have been postulated, it was only very recently that in-depth studies have been carried out to measure the extent to which the long-limb RYGB causes malabsorption. In order to improve care for these patients, specialists who are trained in understanding pathophysiological changes in digestion and absorption after bariatric surgery and who recognize and treat clinical symptoms and nutritional deficits after bariatric surgery are needed. In addition, clinical researchers should take advantage of the experimental setups provided by standardized surgical procedures, and scientific societies should design courses and scientific meetings which combine the expertise in gastroenterology, surgery and nutrition.

Keywords:
Diarrhea, Carbohydrates, Fat, Protein, Roux-en-Y bypass
1.
www.asbs.org.
2.
Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG: Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547–559.
3.
Malinowski SS: Nutritional and metabolic complications of bariatric surgery. Am J Med Sci 2006;331:219–225.
4.
Högenauer C, Hammer HF: Maldigestion and malabsorption; in Feldman M, Friedmann LS, Brandt LJ (eds): Gastrointestinal and Liver Disease. Pathophysiology, Diagnosis, Management, ed 8. Philadelphia, Saunders, 2006, pp 2199–2242.
5.
Griffen WO, Young VL, Stevenson CC: A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977;186:500–509.
6.
Brolin RE, Kenler HA, Gorman JH, Cody RP: Long-limb gastric bypass in the superobese. Ann Surg 1992;215:387–395.
7.
Mason EE, Printen KJ, Hartford CE, Boyd WC: Optimizing results of gastric bypass. Ann Surg 1975;182:405–414.
8.
Savassi-Rocha AL, Diniz MTC, Savassi-Rocha PR, et al: Influence of jejunoileal and common limb length on weight loss following Roux-en-Y gastric bypass. Obes Surg 2008;18:1364–1368.
9.
Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, Porter JL, Asplin J, Kuhn JA, Fordtran JS: The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 2010;92:704–713.
10.
Poitou Bernert C, Ciangura C, Coupaye M, Czernichow S, Bouillot JL, Basdevant A: Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. Diabetes Metab 2007;33:13–24.
11.
Layer P, Liang G, DiMagno E: Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986;251:G475–G480.
12.
Machado JDC, Campos CS, Silva CLD, et al: Intestinal bacterial overgrowth after Roux-en-Y gastric bypass. Obes Surg 2008;18:139–143.
13.
Kim YS, Spritz N, Blum M, Terz J, Sherlock P: The role of altered bile acid metabolism in the steatorrhea of experimental blind loop. J Clin Invest 1966;45:956–962.
14.
Tabaqchali S, Hatzioannou J, Booth CC: Bile-salt deconjugation and steatorrhoea in patients with the stagnant-loop syndrome. Lancet 1968;292:12–16.
15.
Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS: Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethyleneglycol and lactulose. J Clin Invest 1989;84:1056–1062.
16.
Hammer HF, Fine KD, Santa Ana CA, Porter JL, Schiller LR, Fordtran JS: Carbohydrate malabsorption: its measurement and its contribution to diarrhea. J Clin Invest 1990;86:1936–1944.
17.
Fritz E, Hammer HF, Lipp RW, Högenauer C, Stauber RW, Hammer J: Effect of lactulose and polyethylene glycol on colonic transit. Aliment Pharmacol Ther 2005;21:259–268.
18.
Camilleri M, Prather CM: Gastric motor physiology and motor disorders; in Feldman M, Scharschmidt BF, Sleisenger MH (eds): Sleisenger & Fordtran’s GI and Liver Disease, ed 6. Philadelphia, Saunders, 1998, chapter 37, pp 572–586.
19.
Geer RJ, Richards WO, O’Dorisio TM, Woltering EO, et al: Efficacy of octreotide in the treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990;212:678–687.
20.
Lipp RW, Schnedl WJ, Hammer HF, Kotanko P, Leb G, Krejs GJ: Evidence of accelerated gastric emptying in longstanding diabetic patients after ingestion of a semisolid meal. J Nucl Med 1997;38:814–818.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.